Inventor · disambiguated record
Andrew Marcus
Also filed as: MARCUS ANDREW · MARCUS ANDREW P · MARCUS ANDREW PETER
20 granted patents·5 pending applications·261 citations·filing 2002–2025
95Inventor score
Files withVITAE PHARMACEUTICALS LLC9VITAE PHARMACEUTICALS INC8AMGEN SF LLC4GLAXOSMITHKLINE IP DEV LTD2AMGEN INC1
Top patents by PatentIndex Score
25 records- 0195US11479557B2Inhibitors of the menin-MLL interactionVITAE PHARMACEUTICALS LLC·Filed 2020·Granted Oct 25, 2022·4 cites·23 claims
- 0295US9663515B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS INC·Filed 2015·Granted May 30, 2017·13 cites·15 claims
- 0395US9266886B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS INC·Filed 2015·Granted Feb 23, 2016·24 cites·31 claims
- 0494US10047085B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS INC·Filed 2017·Granted Aug 14, 2018·14 cites·20 claims
- 0594US9624217B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS INC·Filed 2016·Granted Apr 18, 2017·14 cites·22 claims
- 0693US10399976B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS LLC·Filed 2018·Granted Sep 3, 2019·11 cites·20 claims
- 0793US9868748B2Thiazolopyrrolidine inhibitors of ROR- γVITAE PHARMACEUTICALS INC·Filed 2014·Granted Jan 16, 2018·13 cites·19 claims
- 0893US9796710B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS INC·Filed 2016·Granted Oct 24, 2017·12 cites·14 claims
- 0992US10087184B2Dihydropyrrolopyridine inhibitors of RORγVITAE PHARMACEUTICALS INC·Filed 2017·Granted Oct 2, 2018·10 cites·13 claims
- 1092US7375102B2Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their useAMGEN SF LLC·Filed 2005·Granted May 20, 2008·27 cites·24 claims
- 1192US7053215B2Substituted Quinazolin-4(3H)-one compounds, compositions, and methods for their useAMGEN SF LLC·Filed 2002·Granted May 30, 2006·47 cites·18 claims
- 1291US12312359B2Inhibitors of the menin-MLL interactionVITAE PHARMACEUTICALS LLC·Filed 2022·Granted May 27, 2025·1 cites·15 claims
- 1391US10683302B2Inhibitors of the menin-MLL interactionVITAE PHARMACEUTICALS LLC·Filed 2017·Granted Jun 16, 2020·9 cites·28 claims
- 1491US7939538B2Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseasesAMGEN INC·Filed 2005·Granted May 10, 2011·20 cites·23 claims
- 1591US7067662B2CXCR3 antagonistsAMGEN SF LLC·Filed 2004·Granted Jun 27, 2006·31 cites·20 claims
- 1687US10807980B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS LLC·Filed 2019·Granted Oct 20, 2020·4 cites·20 claims
- 1786US11535614B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS LLC·Filed 2020·Granted Dec 27, 2022·1 cites·20 claims
- 1880US9845308B2Isoindoline inhibitors of ROR-gammaVITAE PHARMACEUTICALS INC·Filed 2015·Granted Dec 19, 2017·2 cites·12 claims
- 1979US11001583B2Dihydropyrrolopyridine inhibitors of ROR-gammaVITAE PHARMACEUTICALS LLC·Filed 2019·Granted May 11, 2021·1 cites·11 claims
- 2078US2025326764A1Inhibitors of the menin-mll interactionVITAE PHARMACEUTICALS LLC·Filed 2025·Application pending·0 cites
- 2177US7271271B2Imidazolo-related compounds, compositions and methods for their useAMGEN SF LLC·Filed 2005·Granted Sep 18, 2007·3 cites·14 claims
- 2264US2025154288A1Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cellsGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 2361US2020339566A1Dihydropyrrolopyridine inhibitors of ror-gammaVITAE PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 2452US2025136722A1Cytotoxicity targeting chimerasGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Application pending·0 cites
- 2530US2018362485A1N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORSGLAXOSMITHKLINE IP NO 2 LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew Marcus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →